Oxford University Press, Open Forum Infectious Diseases, 5(7), 2020
DOI: 10.1093/ofid/ofaa138
Full text: Download
Abstract We compared risk of recurrent fever in patients with acute myeloid leukemia undergoing induction chemotherapy with febrile neutropenia without an infectious source in which antibacterials were de-escalated before neutrophil recovery versus continued. There was less recurrent fever when antibacterials were de-escalated early with no increased adverse events.